Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

PREOPERATIVE WINDOW OF OPPORTUNITY STUDY WITH GIREDESTRANT (GDC-9545) OR TAMOXIFEN IN PREMENOPAUSAL WOMEN WITH ER[+]/HER2[-] & KI67≥10% EARL… Ended

2023-503565-36-00 ER[+]/HER2[-] & Ki67≥10% early breast cancer (EBC) 4 2023-07-19
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer Ended

2022-502267-37-00 metastatic colorectal cancer 9 2023-07-17
A study to learn how safe the study drug BAY 2416964 (AhR inhibitor) in combination with the treatment pembrolizumab is, how this combinatio… Ended

2023-503547-33-00 Advanced solid tumors 3 2023-07-12
Efficacy of Polatuzumab, Bendamustine and Rituximab in patients with relapsed/refractory mantle cell lymphoma Ended

2024-518704-41-00 Mantle cell lymphoma 4 2023-07-12
A PHASE 1 STUDY TO ASSESS THE MASS BALANCE, PHARMACOKINETICS, AND METABOLISM OF ORAL [14C]-ZIPALERTINIB IN HEALTHY ADULT MALE SUBJECTS Ended

2023-505085-28-00 Cancer 3 2023-07-05
Phase 1 Study of PYX-106 in Solid Tumors Ended

2023-509686-21-00 Solid Tumors 1 2023-07-05
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors Ended

2024-517150-10-00 Cancer 7 2023-06-29
CC-122 Rollover Study Ended

2022-501855-97-00 Multiple Myeloma, Follicular Lymphoma, Diffuse Large B- 3 2023-06-29
Phase 1 Study of BMS-986416 with and without Nivolumab in Solid Tumors Ended

2022-501317-31-00 Solid tumor 2 2023-06-29
A study to investigate the safety and tolerability of intravenous QEQ278 in patients with advanced solid tumors Ended

2022-500540-38-00 Non-small cell lung cancer Oesophageal squamous cell ca 1 2023-06-27
Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (Neo… Ended

2024-515660-31-00 intrahepatic cholangiocarcinoma 4 2023-06-27
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects Wi… Ended

2022-501618-70-00 BRAF-V600 Mutant Solid Tumors including Melanoma, Non-s 7 2023-06-27
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus … Ended

2022-500177-13-00 Metastatic Colorectal Cancer (mCRC) 4 2023-06-02
Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors Ended

2022-500694-14-00 Head and Neck Squamous Cell Cancer 7 2023-06-02
Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. Ended

2024-511292-15-00 Advance Radioactive-Iodine Refractory Differentiated Th 4 2023-05-25
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) Ended

2023-508422-95-00 Cancer 9 2023-05-25
Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed … Ended

2023-509471-17-00 Metastatic or unresectable locally advanced BRAF V600E/ 4 2023-05-24
A Phase 1/2, Umbrella Study of the Efficacy and Safety of Pembrolizumab plus Enfortumab vedotin +/- Investigational Agents in First-Line met… Ended

2023-506385-30-00 Advanced Urothelial Carcinoma 9 2023-05-22
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients wi… Ended

2022-501601-12-00 Diffuse large B-cell Lymphoma 4 2023-05-22
Clinical study to assess safety and efficacy of rapamycin in paediatric high grade glioma Ended

2024-515951-39-00 high grade glioma 4 2023-05-16
Phase 1b study to evaluate MK 0482 for Relapsed/Refractory AML/CMML Ended

2023-503580-42-00 Active CNS leukemia. 3 2023-05-16
An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment-naïve subjects with acute myelogen… Ended

2022-501537-23-00 Acute myeloid leukemia 4 2023-05-16
A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-resistant Prostate Cancer (TAMARACK) Ended

2022-501078-20-00 Metastatic Castration-resistant Prostate Cancer 4 2023-05-15
Comparative Bioavailability of Lenvatinib 10 mg Capsules in Healthy Subjects Ended

2022-501327-25-00 Advanced or recurrent endometrial carcinoma in adults w 2 2023-05-13